التفاصيل البيبلوغرافية
| العنوان: |
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. |
| المؤلفون: |
Wilson, Don P., Jacobson, Terry A., Jones, Peter H., Koschinsky, Marlys L., McNeal, Catherine J., Nordestgaard, Børge G., Orringer, Carl E. |
| المصدر: |
Journal of Clinical Lipidology; Sep2022, Vol. 16 Issue 5, pe77-e95, 19p |
| مصطلحات موضوعية: |
LIPOPROTEINS, BIOMARKERS, GENETICS, STROKE, BLOOD plasma, CARDIOVASCULAR diseases, MYOCARDIAL infarction |
| مستخلص: |
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Lipidology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
